The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL
Kirsten Fischer of the University of Cologne, Cologne, Germany, discusses data on a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and coexisting comorbidities. Dr Fischer presents the results of the CLL14 study (NCT02242942), with a particular emphasis on efficacy and MRD data. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
